NEW ORLEANS — An antithrombotic regimen of apixaban plus a P2Y12 inhibitor such as clopidogrel lowered bleeding events and hospitalizations compared to warfarin plus clopidogrel in a cohort of patients with atrial fibrillation (AFib) and a recent acute coronary syndrome (ACS), according to results of the AUGUSTUS trial.

NEW ORLEANS — Patients who received the MitraClip device to treat heart failure with secondary mitral regurgitation showed significant and lasting improvements on a quality-of-life assessment compared to people treated with optimal medical therapy alone, according to a substudy of the COAPT trial presented at the American College of Cardiology’s scientific sessions.

NEW ORLEANS — Described by its authors as “a one-stop shop” for the primary prevention of cardiovascular disease, a new guideline released March 17 by the American Heart Association (AHA) and the American College of Cardiology (ACC) runs the gamut from smoking cessation strategies to specific recommendations for treating cholesterol based on a patient’s 10-year risk of atherosclerotic cardiovascular disease.

NEW ORLEANS — Two trials evaluating transcatheter aortic valve replacement (TAVR) in low-risk patients haven’t just shifted the TAVR versus surgical AVR discussion. They’ve completely flipped it, said experts here at the American College of Cardiology’s scientific sessions.

The FDA’s preliminary investigation into the long-term safety of paclitaxel-coated balloons and stents revealed those devices are associated with a 50 percent higher risk of death than control devices used to treat femoropopliteal artery disease.

Patients who received aortic valve repair or replacement (AVR) based on Class II indications fared better than those who underwent surgery for Class I triggers in a single-center study, suggesting earlier intervention may be warranted in asymptomatic individuals with chronic aortic regurgitation.

The CDC has released a new fact sheet on the burden of chronic kidney disease (CKD) in the U.S., highlighting its relationship to cardiovascular disease and noting that 15 percent of American adults—or 37 million people—have CKD.

The FDA has expanded the indication for the MitraClip to include heart failure patients with moderate-to-severe secondary mitral regurgitation, the agency announced March 14. Abbott’s transcatheter mitral valve repair device was approved in 2013, but only for primary mitral regurgitation.